Michael Barbella, Managing Editor06.22.24
MPO website visitors apparently couldn't resist Top Companies-member news this past week.
Not surprising, considering this year's edition (Top Companies report) is less than a month from publication. Roche, Boston Scientific Corp., and Medtronic enticed cyberguests with new product and acquisition news, though the trio took a back seat to traffic-topper ZOLL, which captured the pageview crown with remedē System Pivotal Trial results showing favorable outcomes for heart failure (HF) patients via its central sleep apnea (CSA) solution. The analysis re-evaluates pivotal trial data using a win ratio to compare heart failure patients with central sleep apnea when treated with phrenic nerve stimulation (treatment group) versus patients with untreated CSA (control group). The win ratio of 4.92 (95% confidence interval 2.27-10.63, P<0.0001) suggests that patients in the treatment group were nearly five times more likely to experience a clinical benefit compared to those in the control group.
Medtronic was particularly popular among the digital dwelling crowd, landing twice in the top-performing list for its latest aortic guidewire release and personnel move. Roche followed suit with news of the FDA 510(k) clearance of its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), and Boston Scientific Corp. piled up pageviews by announcing its $1.16 billion deal to acquire Silk Road Medical, which boasts a platform of products to prevent stroke in carotid artery disease through transcarotid artery revascularization.
Not surprising, considering this year's edition (Top Companies report) is less than a month from publication. Roche, Boston Scientific Corp., and Medtronic enticed cyberguests with new product and acquisition news, though the trio took a back seat to traffic-topper ZOLL, which captured the pageview crown with remedē System Pivotal Trial results showing favorable outcomes for heart failure (HF) patients via its central sleep apnea (CSA) solution. The analysis re-evaluates pivotal trial data using a win ratio to compare heart failure patients with central sleep apnea when treated with phrenic nerve stimulation (treatment group) versus patients with untreated CSA (control group). The win ratio of 4.92 (95% confidence interval 2.27-10.63, P<0.0001) suggests that patients in the treatment group were nearly five times more likely to experience a clinical benefit compared to those in the control group.
Medtronic was particularly popular among the digital dwelling crowd, landing twice in the top-performing list for its latest aortic guidewire release and personnel move. Roche followed suit with news of the FDA 510(k) clearance of its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), and Boston Scientific Corp. piled up pageviews by announcing its $1.16 billion deal to acquire Silk Road Medical, which boasts a platform of products to prevent stroke in carotid artery disease through transcarotid artery revascularization.